Compare VRTX & JCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | JCI |
|---|---|---|
| Founded | 1989 | 1885 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 85.1B |
| IPO Year | 2006 | 2007 |
| Metric | VRTX | JCI |
|---|---|---|
| Price | $491.20 | $138.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 16 |
| Target Price | ★ $539.69 | $134.60 |
| AVG Volume (30 Days) | 1.3M | ★ 4.2M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | ★ 836.54 | 99.60 |
| EPS | ★ 4.02 | 1.86 |
| Revenue | $2,488,652,000.00 | ★ $9,902,000,000.00 |
| Revenue This Year | $10.79 | $7.61 |
| Revenue Next Year | $10.47 | $6.57 |
| P/E Ratio | $119.31 | ★ $78.31 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $362.50 | $102.09 |
| 52 Week High | $509.98 | $149.38 |
| Indicator | VRTX | JCI |
|---|---|---|
| Relative Strength Index (RSI) | 72.21 | 45.34 |
| Support Level | $420.66 | $137.05 |
| Resistance Level | $506.93 | $145.10 |
| Average True Range (ATR) | 12.22 | 4.58 |
| MACD | 4.26 | -0.44 |
| Stochastic Oscillator | 77.76 | 3.19 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following Johnson Controls' divestiture of its residential and light commercial HVAC businesses to Bosch in 2025, nearly all of its revenue comes from commercial HVAC (60%) and fire and security products and services (40%). A 2016 merger joined Johnson Controls' HVAC and Tyco's fire and security businesses with the premise that there is synergy in offering a broader variety of automation products and solutions to commercial buildings. We estimate Johnson Controls' pro forma revenue mix will be one-third products, one-third installation, and one-third services.